10-Q: Yield10 Bioscience Reports Q2 2024 Results, Focuses on Asset Sale to Nufarm

Sentiment:

Quarterly Report 14 August 2024 4:03 PM

📋All filings for Yield10 Bioscience, INC

Yield10 Bioscience announced its Q2 2024 financial results and is focusing on a potential asset sale to Nufarm, while managing its limited cash resources.

Capital raiseThe company entered into warrant exercise agreements with certain existing institutional investors, resulting in proceeds of approximately $1,174 as of June 30, 2024.The company is pursuing the sale of its remaining assets to Nufarm, which could provide additional capital.

Worse than expectedThe company's financial results indicate a net loss and a decrease in cash and cash equivalents, raising concerns about its financial stability.The company's delisting from the Nasdaq Capital Market and trading on the OTC Markets Group is a negative development that could limit its access to capital.There is substantial doubt about the company's ability to continue as a going concern beyond 2024.

Summary

Yield10 Bioscience reported its financial results for the quarter ended June 30, 2024.
The company is an agricultural bioscience company focused on commercializing sustainable products using the oilseed Camelina sativa.
Yield10 is pursuing two Camelina seed oil products: one for biofuels and another with high levels of omega-3 fatty acids.
The company is headquartered in Woburn, Massachusetts, and has an Oilseed Center of Excellence in Saskatoon, Saskatchewan, Canada.
There is substantial doubt that the company will continue as a going concern beyond 2024.
On July 12, 2024, Yield10 entered into a Memorandum of Understanding (MOU) and License Agreement with Nuseed Nutritional US Inc. (Nufarm) granting Nufarm a commercial license to certain Omega-3 intellectual property assets, materials and know-how for the production of oil in Camelina.
Under the License Agreement, Nufarm will pay Yield10 up to $5,000, of which $3,000 was received upon execution of the agreements during July 2024, with the balance of $2,000 due upon the company's completion of certain near-term milestones.
Yield10 and Nufarm have agreed to negotiate exclusively for the sale of substantially all of Yield10's remaining assets to Nufarm, which will require stockholder approval.
If the asset sale is approved, Yield10 will likely complete the sale, wind down its affairs, and cease operations shortly thereafter.
On May 2, 2024, the Company effected a 1-for-24 reverse stock split of its common stock.
On May 14, 2024, Yield10 received notice from The Nasdaq Stock Market LLC that the Nasdaq Hearings Panel had determined to delist the Company's common stock.
Suspension of trading in our common stock on Nasdaq became effective at the open of trading on May 16, 2024.
Yield10's common stock began trading on the OTC Markets Group (OTC) platform at the open of trading on May 16, 2024, under the symbol YTEN.
On July 19, 2024, the Company's common stock began trading on the OTC-QB market.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's financial challenges, delisting from Nasdaq, and uncertainty about its future as a going concern, despite the positive licensing agreement with Nufarm and potential asset sale.

Positives

Yield10 secured a licensing agreement with Nufarm for its Omega-3 intellectual property, providing an immediate influx of $3 million and potential for an additional $2 million upon achieving milestones.
The company is actively pursuing the sale of its remaining assets to Nufarm, which could provide additional capital and a path to resolving its financial challenges.
The company recognized $450 in license revenue for the three months ended June 30, 2024, from the VISION Bioenergy Oilseeds, LLC agreement.
The company recognized $750 in license revenue for the six months ended June 30, 2024, from the VISION Bioenergy Oilseeds, LLC agreement.

Negatives

There is substantial doubt about Yield10's ability to continue as a going concern beyond 2024.
The company has a significant accumulated deficit of $419.9 million as of June 30, 2024.
The company's unrestricted cash and cash equivalents totaled $733 as of June 30, 2024, a decrease from $1,068 at December 31, 2023.
The company's common stock was delisted from the Nasdaq Capital Market and is now trading on the OTC Markets Group.

Risks

The proposed asset sale to Nufarm is subject to stockholder approval and may not be completed on favorable terms or at all.
The announcement and pendency of the proposed asset sale may adversely affect the company's business and relationships with third parties.
The company's limited cash resources and uncertainty about securing additional funding pose significant risks to its operations.
The delisting of the company's common stock from the Nasdaq Capital Market may result in a less liquid market and make it more difficult to raise funds.
The company's recently implemented reverse stock split could adversely affect the market liquidity of its common stock.

Future Outlook

The company anticipates that funds received from Nufarm will serve as its primary source of working capital as it seeks to wind down its operations and satisfy its remaining obligations by the end of 2024.

Management Comments

Management believes that funds received from Nufarm will serve as the primary source of working capital as the company seeks to wind down operations and satisfy remaining obligations by the end of 2024.

Industry Context

Yield10's focus on Camelina as a platform crop aligns with the growing demand for sustainable biofuels and omega-3 feedstocks, but the company faces challenges in scaling up production and commercializing its products.

Comparison to Industry Standards

It is difficult to compare Yield10's results directly to industry standards due to its unique focus on Camelina and its early stage of commercialization.
Companies like Arcadia Biosciences, Inc. (RKDA) also focus on crop improvement but have different target markets and technologies.
Compared to larger agricultural companies like Bayer or Corteva, Yield10's revenue is significantly smaller, reflecting its early stage and niche focus.
The licensing agreement with Nufarm is a positive step, but the company's long-term viability depends on its ability to successfully commercialize its Camelina products or complete the asset sale.

Stakeholder Impact

Shareholders face uncertainty regarding the value of their investment due to the company's financial challenges and potential asset sale.
Employees may be affected by the company's plans to wind down operations and discontinue its business.
Customers and partners may need to find alternative suppliers or collaborators if the company ceases operations.

Next Steps

The company plans to hold a special meeting of stockholders to seek approval for the asset sale to Nufarm.
The company will continue to negotiate the terms of the asset purchase agreement with Nufarm.
The company will focus on winding down its operations and satisfying its remaining obligations by the end of 2024.

Key Dates

Date	Description
2016-10-31	Original lease commencement for Woburn, MA facility.
2016-12-31	Original lease agreement date for Woburn, MA facility.
2018-05-17	Date of license agreement with the University of Missouri.
2020-11-01	Date of exclusive collaboration agreement with Rothamsted Research.
2023-04-27	Date of signing non-binding LOI with Marathon Petroleum Corporation.
2023-05-03	Date of registered direct offering and private placement.
2023-08-15	Date of closing public offering.
2024-02-14	Date of granting global non-exclusive commercial license to VISION Bioenergy Oilseeds LLC.
2024-03-22	Date of entering into warrant exercise agreements with certain existing institutional investors.
2024-04-26	Stockholders approved an amendment to our Amended and Restated Certificate of Incorporation, as amended, and authorized our Board of Directors, if in their judgment they deemed it necessary, to effect a reverse stock split of our common stock at a ratio in the range of 5:1 to 25:1.
2024-05-02	Effective date of 1-for-24 reverse stock split.
2024-05-14	Date of receiving delisting notice from Nasdaq.
2024-05-16	Suspension of trading on Nasdaq and start of trading on OTC Markets Group.
2024-06-07	Date of 2024 Annual Meeting, at which stockholders approved an amendment to the Certificate of Incorporation to increase from 60 million shares to 150 million shares the aggregate number of shares of common stock that are authorized to be issued.
2024-07-12	Date of entering into MOU and License Agreement with Nuseed Nutritional US Inc. (Nufarm).
2024-07-19	Date of common stock began trading on the OTC-QB market.
2024-07-23	Date of mutually agreeing to terminate the Convertible Note with MPC.

Keywords

Yield10 Bioscience, Nufarm, asset sale, Omega-3, Camelina, licensing agreement, financial results, going concern, reverse stock split, delisting

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.